The British consumer goods company Reckitt Benckiser is buying K-Y personal lubricants from U.S. health care giant Johnson & Johnson. Terms of the deal were not disclosed Monday by Reckitt Benckiser, which expects to close the acquisition by the middle of the year.
Subsidiaries of Johnson & Johnson have agreed to pay $5.9 million to settle a lawsuit with...
The contractor working for New Jersey's largest utility at the site of a town house explosion...
A federal judge has ruled in favor of a manufacturer in a lawsuit brought by a Texas woman who claimed her pelvic pain was caused by implanted surgical mesh. U.S. District Judge Joseph R. Goodwin on Tuesday dismissed Carolyn Lewis' lawsuit against Johnson & Johnson subsidiary Ethicon.
The Food and Drug Administration has rejected — for a third time — Johnson & Johnson's application to expand use of the blood thinner Xarelto to reduce dangerous blood clots and related problems in patients with coronary artery disease.
A dozen plaintiffs filed the lawsuit in Texas in 2012. It is among about 50,000 cases filed nationwide that were transferred to West Virginia as part of federal multidistrict litigation. U.S. District Judge Joseph R. Goodwin selected the lawsuit and several other "bellwether" cases to serve as representative cases.
Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.
A divided Louisiana Supreme Court has overturned a $330 million judgment against two pharmaceutical companies that state Attorney General James "Buddy" Caldwell accused of improperly marketing a drug.
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs.
Johnson & Johnson today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012.
A proposed transaction between Johnson & Johnson (JNJ) and The Carlyle Group is viewed as strategically sound, according to Fitch Ratings. Fitch believes the margins and long-term growth opportunities for this business had been lower versus those for the total firm.
A panel of Food and Drug Administration experts again rejected Johnson & Johnson's bid to expand use of its blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease. The condition occurs when narrowed blood vessels restrict blood flow to the heart, increasing the risk of heart attack and other potentially deadly problems.
The Carlyle Group has agreed to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 billion.
The Arkansas Supreme Court has scheduled oral arguments in Johnson & Johnson's request to overturn a verdict and $1.2 billion fine over the marketing of the antipsychotics drug Risperdal.
Shares of Johnson & Johnson moved higher Tuesday after an RBC Capital Markets analyst upgraded the stock, saying he expects strong sales of the company's newest drugs.
Johnson & Johnson is paying North Dakota $923,000 as part of a $1.2 billion national settlement over allegations it illegally promoted two of its best-selling antipsychotics drugs. The state Department of Human Services says North Dakota's share of proceeds comes from a settlement announced last month.
The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.
The Food and Drug Administration said Wednesday that it reached a $1.25 million settlement with a division of Johnson & Johnson over allegations that it knowingly shipped faulty sterilization equipment used by hospitals.
Federal regulators on Friday approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections. The U.S. Food and Drug Administration said it approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.
Johnson & Johnson said late Tuesday that it will pay $2.5 billion to settle thousands of lawsuits brought by hip replacement patients who accuse the company of selling faulty implants that led to injuries and additional surgeries.
Ohio's Medicaid program will receive $52.7 million through a national settlement with a pharmaceutical company. The $2.2 billion settlement announced Monday involves Johnson & Johnson, one of its subsidiaries, the federal government and several states.
Johnson & Johnson has agreed to pay over $2.2 billion to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients, the Department of Justice announced on Monday.
An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.
The Food and Drug Administration holds a public meeting this week to review two experimental medications from Johnson & Johnson and Gilead Sciences. The new drugs, if approved, could offer a quicker, more effective approach to eliminating hepatitis C, a blood-borne disease blamed for 15,000 deaths in the U.S. this year.
An experimental hepatitis C drug from Johnson & Johnson appears to be slightly more effective at eliminating the virus than currently available treatments, though federal safety reviewers say it also causes rash and sunburn in some patients. The Food and Drug Administration posted its review...
Johnson & Johnson today announced sales of $17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third quarter of 2012. Operational results increased 4.7% and the negative impact of currency was 1.6%. Domestic sales increased 1.7%. International sales increased 4.2%, reflecting operational growth of 7.1% and a negative currency impact of 2.9%.
Johnson & Johnson, which reports third-quarter results before the stock market opens Tuesday, likely will focus on experimental drugs under review by regulators and sales of its newest products. The world's largest maker of health care products likely will tout its August acquisition of Aragon Pharmaceuticals, which is developing drugs for hormonally driven cancers, and its pipeline of experimental drugs.
A federal jury in Sioux Falls has found that a woman's use of Johnson & Johnson products that contained talcum contributed to her ovarian cancer. The Argus Leader reports that the jury said Friday that Johnson & Johnson should warn consumers of the link...
- Page 1